Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus

dc.contributor.authorFloris, Alberto
dc.contributor.authorPiga, Matteo
dc.contributor.authorMangoni, Arduino Aleksander
dc.contributor.authorBortoluzzi, Alessandra
dc.contributor.authorErre, Gian Luca
dc.contributor.authorCauli, Alberto
dc.date.accessioned2018-03-04T23:20:46Z
dc.date.available2018-03-04T23:20:46Z
dc.date.issued2018-02-18
dc.date.updated2018-02-25T06:52:24Z
dc.descriptionThis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.description.abstractCardiovascular (CV) morbidity and mortality are a challenge in management of patients with systemic lupus erythematosus (SLE). Higher risk of CV disease in SLE patients is mostly related to accelerated atherosclerosis. Nevertheless, high prevalence of traditional cardiovascular risk factors in SLE patients does not fully explain the increased CV risk. Despite the pathological bases of accelerated atherosclerosis are not fully understood, it is thought that this process is driven by the complex interplay between SLE and atherosclerosis pathogenesis. Hydroxychloroquine (HCQ) is a cornerstone in treatment of SLE patients and has been thought to exert a broad spectrum of beneficial effects on disease activity, prevention of damage accrual, and mortality. Furthermore, HCQ is thought to protect against accelerated atherosclerosis targeting toll-like receptor signaling, cytokine production, T-cell and monocyte activation, oxidative stress, and endothelial dysfunction. HCQ was also described to have beneficial effects on traditional CV risk factors, such as dyslipidemia and diabetes. In conclusion, despite lacking randomized controlled trials unambiguously proving the protection of HCQ against accelerated atherosclerosis and incidence of CV events in SLE patients, evidence analyzed in this review is in favor of its beneficial effect.
dc.identifier.citationAlberto Floris, Matteo Piga, Arduino Aleksander Mangoni, Alessandra Bortoluzzi, Gian Luca Erre, and Alberto Cauli, “Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus,” Mediators of Inflammation, vol. 2018, Article ID 3424136, 11 pages, 2018. doi:10.1155/2018/3424136
dc.identifier.doihttps://doi.org/10.1155/2018/3424136
dc.identifier.urihttps://doi.org/10.1155/2018/3424136
dc.identifier.urihttp://hdl.handle.net/2328/37766
dc.language.isoenen
dc.oaire.license.condition.licenseCC-BY
dc.publisherHindawien
dc.rightsCopyright © 2018 Alberto Floris et al.
dc.rights.holderAlberto Floris et al.
dc.titleProtective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosusen
dc.typeArticleen
local.contributor.authorOrcidLookupMangoni, Arduino Aleksander: https://orcid.org/0000-0001-8699-1412en_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
MI.2018.3424136.pdf
Size:
869.58 KB
Format:
Adobe Portable Document Format
Description:
Publisher version
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.84 KB
Format:
Item-specific license agreed upon to submission
Description: